• Gerald M. Woerlee
Part of the Developments in Critical Care Medicine and Anesthesiolgy book series (DCCA, volume 26)


The previous chapter discussed the distribution of an intravenously administered drug within the body. Being able to describe the change of plasma concentration of a drug with time after administration is all very well, but is a rather sterile mathematical pastime to many clinicians. Clinicians are pragmatic people who also want to know if a given dose of a drug will have an effect, and how long that effect is likely to last.


Drug Concentration Plasma Drug Concentration Anesthetic Drug Single Intravenous Dose Effect Compartment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hull CJ, et al: A pharmacodynamic model for pancuronium. British Journal of Anaesthesia, 1978: 50: 1113–1123.CrossRefPubMedGoogle Scholar
  2. 2.
    Sheiner LB, et al: Simultaneous modelling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clinical Pharmacology & Therapeutics, 1979: 25: 358–371.Google Scholar
  3. 3.
    Waud BE, Waud DR: The relation between the response to “train-of-four” stimulation and receptor occlusion during competitive neuromuscular block. Anesthesiology, 1972: 37: 413–416.CrossRefPubMedGoogle Scholar
  4. 4.
    Yodlowski EH, Mortimer JT: The relationship between receptor occlusion and the frequency sweep electromyogram during competitive neuromuscular blockade. Anesthesiology, 1981: 54: 23–28.CrossRefPubMedGoogle Scholar
  5. 5.
    Shanks CA: Pharmacokinetics of the nondepolarizing neuromuscular applied to calculation of bolus and infusion dosage regimes. Anesthesiology, 1986: 64: 72–86.CrossRefPubMedGoogle Scholar
  6. 6.
    Hennis PJ, Stanski DR: Pharmacokinetic and pharmacodynamic factors that govern the clinical use of muscle relaxants. Seminars in Anesthesia, 1985: 4: 21–30.Google Scholar
  7. 8.
    Holford NHG, Sheiner LB: Understanding the dose effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clinical Pharmacokinetics, 1981: 6: 429–453.CrossRefPubMedGoogle Scholar
  8. 9.
    Wingard LB, Cook DR: Pharmacodynamics of tubocurarine in humans. British Journal of Anaesthesia, 1976: 48: 839–845.CrossRefPubMedGoogle Scholar
  9. 10.
    Becker KE: Plasma levels of thiopental necessary for anesthesia. Anesthesiology, 1978: 49: 192–196.CrossRefPubMedGoogle Scholar
  10. 11.
    Hudson RJ, et al: A model for studying depth of anesthesia and acute tolerance to thiopental. Anesthesiology, 1983: 59: 301–308.CrossRefPubMedGoogle Scholar
  11. 12.
    Kissin I, et al: Inotropic and anesthetic potencies of etomidate and thiopental in dogs. Anesthesia and Analgesia, 1983: 62: 961–965.CrossRefPubMedGoogle Scholar
  12. 13.
    Lauven PM, et al: Venous threshold concentrations of methohexitone. Anesthesiology, 1985: 63: A368.CrossRefGoogle Scholar
  13. 14.
    Todd MM, et al: The hemodynamic consequences of high-dose methohexital anesthesia in humans. Anesthesiology, 1984: 61: 495–501.CrossRefPubMedGoogle Scholar
  14. 15.
    Schüttler J, et al: Infusion strategies to investigate the pharmacokinetics and pharmacodynamics of hypnotic drugs: etomidate as an example. European Journal of Anesthesiology, 1985: 2: 133–142.Google Scholar
  15. 16.
    Lemmens HJM, et al: Age has no effect on the pharmacodynamics of alfentanil. Anesthesia and Analgesia, 1988: 67: 956–960.CrossRefPubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1992

Authors and Affiliations

  • Gerald M. Woerlee
    • 1
  1. 1.Rijnoord HospitalAlphen aan den RijnThe Netherlands

Personalised recommendations